Market accessCompany release

AVITA Medical lifts 2026 revenue guidance to $92-94 million after 53% third-quarter growth

🇺🇸 AVITA Medical, Inc. (RCEL) · Thu 05 Nov 2026

The RECELL maker reported $26.1 million in Q3 revenue, drew the last $10 million of its Perceptive Advisors facility and removed its going-concern qualification.

AVITA Medical, maker of the RECELL skin-regeneration system and the Cohealyx and PermeaDerm wound products, reported third-quarter 2026 results on 5 November 2026. Revenue reached $26.1 million, a 53% increase on the comparable period.

The company raised its full-year 2026 revenue guidance to a range of $92 million to $94 million.

On the financing side, AVITA drew the final $10 million tranche of its credit facility with Perceptive Advisors. The company also dropped its going-concern qualification, a notation that signals doubt about a company's ability to continue operating over the coming year.

On reimbursement, the US Centers for Medicare & Medicaid Services (CMS) has finalised physician payment values for RECELL procedures and simplified the associated billing codes. The changes take effect on 1 January 2027. The summary provided does not give the payment amounts or the specific codes affected.

What it means for your team

  • Market-access teams should check the finalised CMS physician payment values and simplified billing codes ahead of their 1 January 2027 start, as the figures were not disclosed in the summary.
  • Providers and billing staff using RECELL will need to prepare for the coding changes before the effective date.
  • The removal of the going-concern qualification and the fully drawn credit facility may be relevant to supplier-risk assessments for the company's products.

Company's press release (SEC filing): AVITA Medical, Inc. ↗

Article written by VigiEye from the official source (AVITA Medical, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →